These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 22331668

  • 1. Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening.
    Vujosevic S, Tempesta D, Noventa F, Midena E, Sebastiani G.
    Hepatology; 2012 Aug; 56(2):455-63. PubMed ID: 22331668
    [Abstract] [Full Text] [Related]

  • 2. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N, Besheer T, Gad Y, Elbendary A, Mokbel T, Abdel-Aziz A.
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
    [Abstract] [Full Text] [Related]

  • 3. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
    Fouad YM, Khalaf H, Ibraheem H, Rady H, Helmy AK.
    Int J Infect Dis; 2012 Jan; 16(1):e67-71. PubMed ID: 22115957
    [Abstract] [Full Text] [Related]

  • 4. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C, Pérez-Álvarez R.
    Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH.
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [Abstract] [Full Text] [Related]

  • 6. Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C.
    Adams S, Ostermeier M.
    Optometry; 2010 Nov; 81(11):580-6. PubMed ID: 20655283
    [Abstract] [Full Text] [Related]

  • 7. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection.
    Panetta JD, Gilani N.
    Aliment Pharmacol Ther; 2009 Sep 15; 30(6):597-602. PubMed ID: 19549263
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study [KULDS] Group.
    J Gastroenterol Hepatol; 2012 Jul 15; 27(7):1233-40. PubMed ID: 22098185
    [Abstract] [Full Text] [Related]

  • 9. [Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
    Kupś-Rzepecka J, Woźniakowska-Gesicka T, Gołabek V.
    Przegl Lek; 2011 Jul 15; 68(6):311-5. PubMed ID: 22039668
    [Abstract] [Full Text] [Related]

  • 10. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Gluhovschi C, Gadalean F, Kaycsa A, Curescu M, Sporea I, Gluhovschi G, Petrica L, Velciov S, Bozdog G, Bob F, Vernic C, Cioca D.
    Immunopharmacol Immunotoxicol; 2011 Dec 15; 33(4):744-50. PubMed ID: 21320001
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C.
    Sanai FM, Mousa D, Al-Mdani A, Al-Shoail G, Al-Ashgar H, Al Meshari K, Al-Qahtani A, Saadeh M, Bzeizi KI, Aleid H.
    J Hepatol; 2013 Jun 15; 58(6):1096-103. PubMed ID: 23428875
    [Abstract] [Full Text] [Related]

  • 12. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.
    Kim ET, Kim LH, Lee JI, Chin HS.
    Jpn J Ophthalmol; 2009 Nov 15; 53(6):598-602. PubMed ID: 20020238
    [Abstract] [Full Text] [Related]

  • 13. Retinal vascular complications associated with interferon-ribavirin therapy for chronic hepatitis C: A population-based study.
    Lai CH, Yang YH, Chen PC, King YC, Liu CY.
    Pharmacoepidemiol Drug Saf; 2018 Feb 15; 27(2):191-198. PubMed ID: 29210149
    [Abstract] [Full Text] [Related]

  • 14. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
    Slim J, Afridi MS.
    Infect Dis Clin North Am; 2012 Dec 15; 26(4):917-29. PubMed ID: 23083824
    [Abstract] [Full Text] [Related]

  • 15. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
    Klimacka-Nawrot E, Musialik J, Suchecka W, Petelenz M, Hartman M, Lichtański P, Błońska-Fajfrowska B.
    Wiad Lek; 2010 Dec 15; 63(4):289-99. PubMed ID: 21608370
    [Abstract] [Full Text] [Related]

  • 16. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
    Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM.
    Hepatology; 2012 Aug 15; 56(2):464-73. PubMed ID: 22334369
    [Abstract] [Full Text] [Related]

  • 17. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
    Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A, Chuang WL, Lee CM, George J, Gould M, Flisiak R, Jacobson IM, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Sola R, Messina I, Yin Y, Cammarata S, Feutren G, Brown KK.
    J Viral Hepat; 2013 Apr 15; 20(4):e115-23. PubMed ID: 23490379
    [Abstract] [Full Text] [Related]

  • 18. [Bilateral non-arteritic ischemic optic neuropathy during treatment of viral hepatitis C with pegylated interferon and Ribavirin].
    Iferkhass S, Elasri F, Chatioui S, Khoyaali A, Bargach T, Reda K, Oubaaz A.
    J Fr Ophtalmol; 2015 Jan 15; 38(1):34-40. PubMed ID: 25533994
    [Abstract] [Full Text] [Related]

  • 19. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
    Fabris P, Carlotto A, Del Bianco T, Malfatti F, Tramarin A, Miotti MA, Baldo V, Floreani A, Giordani MT, Grasso A.
    Eur J Gastroenterol Hepatol; 2013 Dec 15; 25(12):1396-401. PubMed ID: 23743559
    [Abstract] [Full Text] [Related]

  • 20. Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.
    Vartany E, Caldwell CA, Trow TK.
    Heart Lung; 2008 Dec 15; 37(2):153-6. PubMed ID: 18371508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.